Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Oxycodone HCl controlled-release Clear all
Completed Not applicable Interventional Results available

A Pilot Study Investigating the nCAP Signal Relief Patch in Subjects Undergoing Primary Hip or Knee Replacement Surgery

NCT05252858
View directory record Official record
Conditions
Opioid Use, Pain, Post Operative
Interventions
nCAP Signal Relief Patch, Standard of Care
Device · Other
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets

NCT00853268
View directory record Official record
Conditions
Healthy
Interventions
Controlled-Release Oxycodone Hydrochloride 40 mg, OxyContin® 40 mg tablet
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 21, 2026, 10:40 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Optimizing Pain Control in Transurethral Resection of the Prostate

NCT04102566
View directory record Official record
Conditions
Pain, BPH With Urinary Obstruction, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions
Ibuprofen 600 mg, Education
Drug · Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 3 Interventional Results available

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

NCT02740114
View directory record Official record
Conditions
Malignant Neoplasms of Female Genital Organs, Gynecologic Cancer
Interventions
Bupivacaine, Liposomal Bupivacaine, Oxycodone, Pill Diary, Symptom Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Not applicable Interventional Results available

Liposomal Bupivacaine in Implant Based Breast Reconstruction

NCT02659501
View directory record Official record
Conditions
Breast Cancer, Postoperative Pain
Interventions
Liposomal bupivacaine, Bupivacaine with epinephrine, Morphine sulfate, Hydrocodone/acetaminophen, Diazepam
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 21, 2026, 10:40 AM EDT
Suspended Phase 4 Interventional

Opioid Reduction Toolkit Reduces Opioids Prescribed and Consumed

NCT05363436
View directory record Official record
Conditions
Opioid Abuse, Opioid Misuse, Pain
Interventions
Oxycodone
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 99 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 21, 2026, 10:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Hip Arthroscopy Postoperative Opioid Demands

NCT04094701
View directory record Official record
Conditions
Opioid Use, Pain, Femoral Acetabular Impingement, Labral Tear, Glenoid
Interventions
Control Group Regimen, Opioid reduced regimen
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

NCT05571345
View directory record Official record
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone Hydrochloride 40 mg, Placebo
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee

NCT00979953
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
ADL5859, ADL5747, Oxycodone CR, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Daytona Beach, Florida • Stockbridge, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2015 · Synced Oct 21, 2026, 10:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

NCT01677065
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone controlled-release test formulation, Immediate-release reference drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

NCT00364533
View directory record Official record
Conditions
Arthroplasty
Interventions
Tapentadol IR (CG5503), Placebo, Oxycodone HCL IR
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
45
States / cities
Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

NCT01192295
View directory record Official record
Conditions
Pain
Interventions
Oxycodone HCl controlled-release tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 16 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01427283
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
149
States / cities
Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized-controlled Trial of Post-operative Opiate Quantities After Urogynecologic Surgery

NCT03319277
View directory record Official record
Conditions
Postoperative Pain, Opioid Use
Interventions
Decreased opiate prescription, Routine opiate prescription
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 21, 2026, 10:40 AM EDT
Recruiting Phase 3 Interventional

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

NCT03823534
View directory record Official record
Conditions
Bone Metastases, Lymphoma, Multiple Myeloma, Opioid Use, Pain
Interventions
Ketorolac, Normal saline, Acetaminophen, Oxycodone Acetaminophen, Morphine, Hydrocodone/Acetaminophen, Oxycodone
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section

NCT03372382
View directory record Official record
Conditions
Opioid Use, Pain, Postoperative
Interventions
Ibuprofen, Acetaminophen, Norco
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation

NCT01677039
View directory record Official record
Conditions
Healthy
Interventions
Test formulation administered with water, Test formulation administered with 20% ethanol, Test formulation administered with 40% ethanol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 21, 2026, 10:40 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis

NCT02452437
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Oxycodone
Drug
Lead sponsor
Emerio & Lourdes Linares Research and Education Center
Other
Eligibility
30 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2015 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Not applicable Interventional Results available

Postoperative Nudges to Reduce Opioid Prescribing

NCT05070338
View directory record Official record
Conditions
Opioid Prescribing
Interventions
Guideline-Based (Injunctive Norm) Nudges, Peer-Based (Social Norm) Nudges
Behavioral
Lead sponsor
RAND
Other
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Results available

ICE-T Pain Regimen for Total Laparoscopic Hysterectomy

NCT03987022
View directory record Official record
Conditions
Opioid Substitution Treatment
Interventions
Ketorolac, Opioids, Ice Packs, Tylenol, Motrin, Dilaudid Injectable Product, Percocet 5Mg-325Mg Tablet
Drug · Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 3 Interventional Results available

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

NCT00771758
View directory record Official record
Conditions
Back Pain
Interventions
oxycodone IR, placebo, tapentadol IR
Drug
Lead sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Haleyville, Alabama • Tallassee, Alabama • Peoria, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 21, 2026, 10:40 AM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

NCT01063868
View directory record Official record
Conditions
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
Interventions
Tapentadol extended release (ER), Oxycodone controlled release (CR)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
23
States / cities
Mesa, Arizona • Tucson, Arizona • Fruitland Park, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 21, 2026, 10:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Toward Zero Prescribed Opioids for Outpatient General Surgery

NCT05327777
View directory record Official record
Conditions
Opioid Misuse and Addiction, Pain
Interventions
Oxycodone, Zero Opioid Protocol
Drug · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 99 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 21, 2026, 10:40 AM EDT